Get the Stockscreener App
9.48
7.36%
0.65
After Hours:
9.36
-0.12
-1.27%
Kala Bio Inc stock is traded at $9.48, with a volume of 68,971.
It is up +7.36% in the last 24 hours and up +37.99% over the past month.
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.
See More
Previous Close:
$8.83
Open:
$8.85
24h Volume:
68,971
Relative Volume:
1.63
Market Cap:
$57.74M
Revenue:
$5.75M
Net Income/Loss:
$-38.96M
P/E Ratio:
-0.7602
EPS:
-12.47
Net Cash Flow:
$-32.63M
1W Performance:
+16.32%
1M Performance:
+37.99%
6M Performance:
+46.52%
1Y Performance:
+34.66%
1-Day Range:
$8.3401
$9.74
1-Week Range:
$7.84
$9.74
52-Week Range:
$4.21
$9.74
Kala Bio Inc Stock (KALA) Company Profile
Name
Kala Bio Inc
Sector
Industry
Phone
781-996-5252
Address
1167 MASSACHUSETTS AVENUE, ARLINGTON, MA
Compare KALA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KALA
Kala Bio Inc
|
9.48 | 57.74M | 5.75M | -38.96M | -32.63M | -12.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.40 | 112.90B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
683.08 | 75.06B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
665.68 | 40.45B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
277.16 | 35.75B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
120.88 | 28.98B | 3.30B | -501.07M | 1.03B | -2.1146 |
Kala Bio Inc Stock (KALA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-30-22 | Downgrade | JP Morgan | Neutral → Underweight |
| Aug-06-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-14-20 | Downgrade | Jefferies | Buy → Hold |
| Jul-23-20 | Initiated | Northland Capital | Outperform |
| Jun-01-20 | Resumed | Oppenheimer | Outperform |
| May-27-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-09-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Dec-17-19 | Downgrade | BofA/Merrill | Buy → Neutral |
| Mar-14-19 | Initiated | Jefferies | Buy |
View All
Kala Bio Inc Stock (KALA) Latest News
KALA stock soars to 52-week high, reaching $8.81 By Investing.com - Investing.com Australia
KALA stock soars to 52-week high, reaching $8.81 - Investing.com
Ramesh Lal Kala , IND candidate bio : Assets , Total Income , Liabilities , Criminal Cases and other details. - The Hindu
KALA BIO Announces $10.75 Million Private Placement Agreement - WilmerHale
Precision Bio stock upgraded at BMO (update) (DTIL:NASDAQ) - Seeking Alpha
Kala Bio executive Todd Bazemore sells $15,206 in stock By Investing.com - Investing.com Australia
Kala Bio's head of research sells $18,662 in stock - Investing.com India
Kala Bio CEO Mark Iwicki sells $44,093 in stock - Investing.com India
Kala Bio's chief business officer sells $15,420 in stock By Investing.com - Investing.com South Africa
Kala Bio’s chief business officer sells $15,420 in stock By Investing.com - Investing.com Nigeria
Kala Bio's head of research sells $18,662 in stock By Investing.com - Investing.com South Africa
Kala Bio CFO Mary Reumuth sells $13,016 in company stock By Investing.com - Investing.com Nigeria
Kala Bio CFO Mary Reumuth sells $13,016 in company stock - Investing.com
Kala Bio's chief business officer sells $15,420 in stock - Investing.com
Baker Bros. Advisors LP Increases Stake in Kala Bio Inc - GuruFocus.com
Baker Bros. Advisors buys $2 million in Kala Bio shares By Investing.com - Investing.com Australia
KALA BIO announces $10.75M private placement - MSN
Baker Bros. Advisors buys $2 million in Kala Bio shares - Investing.com
KALA BIO Announces Private Placement Agreement with Institutional Investors - Defense World
Kala Bio raises $10.75 million in private placement By Investing.com - Investing.com Canada
KALA BIO Secures $10.75 Million in Private Placement to Advance Eye Disease Treatments - Tandav Media
Kala Bio raises $10.75 million in private placement - Investing.com India
KALA Bio Secures $10.75 Million for Eye Disease Treatments: What’s Next for the Biopharma Stock? - Tandav Media
KALA BIO Announces $10,750,000 Private Placement - GlobeNewswire
Global Engine Group Holding Limited Acquires 22.5% Stake in Corpotech Holdings Limited, a Hong Kong Data Centre Operator - The Manila Times
KALA BIO Secures $10.75M Investment from Major Funds, Extends Cash Runway for Key Eye Treatment Trial - StockTitan
Exicure joins hands with GPCR Therapeutics for growth in biotech (NASDAQ:XCUR) - Seeking Alpha
RBC Capital Downgrades HOOKIPA Pharma (HOOK) - MSN
KALA BIO (KALA) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? - Zacks Investment Research
Tracking Baker Brothers Portfolio – Q3 2024 Update - Seeking Alpha
Kala Bio (LTS:0JQ2) EV-to-Revenue : (As of Nov. 30, 2024) - GuruFocus.com
KALAKALA BIO, Inc. Latest Stock News & Market Updates - StockTitan
FTC Solar Announces Reverse Stock Split - The Manila Times
KALA BIO to Present at Piper Sandler Healthcare Conference, Showcasing Eye Disease Pipeline | KALA Stock News - StockTitan
KALA BIO to Present at Piper Sandler 36th Annual Healthcare Conference - GlobeNewswire
2024 Pharmaceutical Executive APEX Award Winners - Pharmaceutical Executive
Kala Pharmaceuticals Announces IND Submission of its MPP-Formulated Loteprednol Etonbonate (LE-MPP) for Post-Cataract Surgery - Marketscreener.com
Kala Pharmaceuticals retains stock target with Buy rating on trial progress - Investing.com India
60 Degrees Pharmaceuticals’ (SXTP) Neutral Rating Reaffirmed at HC Wainwright - Defense World
Walt Disney (NYSE:DIS) Price Target Raised to $130.00 - Defense World
KALA BIO’s (KALA) Buy Rating Reaffirmed at HC Wainwright - Defense World
ADAR1 Capital Management, LLC Increases Stake in Kala Bio Inc - GuruFocus.com
KALA BIO, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Kala Bio Advances PCED Treatment Amid Financial Update - TipRanks
KALA BIO: Q3 Earnings Snapshot - mySA
Kala Bio Inc Stock (KALA) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.49%
0.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):